RxDoctor Payments Data

Jenna Harper

Gerontology · Meridian, MSNPI 1568911527

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 77 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 63.1% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2023 at $369 and has fallen 92.1% since, to $29 in 2025.

$1,060in general payments, 2019–2025

Across 77 payments — averaging $13.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$669
  • AstraZeneca$103
  • Novo Nordisk$74
  • Lilly USA, LLC$52
  • Abbott$48
  • Avanir Pharmaceuticals, Inc.$31
  • plus $84 from 4 others

What the payments were for

  • Food & beverage$1,060100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,060 in reported general payments places this provider in the 55th percentile of 66 gerontology providers in Mississippi.

See all gerontology providers in Mississippi

Medicare billing

Part B allowed, 2024
$4,138
Medicare patients
44
Services billed
67

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide19$25,967
VraylarCariprazine Hcl17$22,926
Albuterol Sulfate HfaAlbuterol Sulfate27$1,105
Rosuvastatin Calcium74$704
Gabapentin29$505
Risperidone12$438
Omeprazole26$349
Oxybutynin Chloride ErOxybutynin Chloride21$336
Valsartan13$257
Pantoprazole Sodium27$255
Fluticasone Propionate11$235
Atorvastatin Calcium40$226
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide11$219
Hydralazine Hcl15$216
Clonidine Hcl20$203

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$74$25,96719 claims
AbbVieVraylar$669$22,92617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 66 gerontology providers in Mississippi.

Other gerontology in Meridian

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →